RÉSUMÉ
Alzheimer's disease is associated with the accumulation of amyloid-ß (Aß) in the brain. In particular, the 42-amino acid form, Aß1-42, is thought to play a key role in the disease. It is therefore of interest that diverse compounds, known as γ-secretase modulators (GSM), can selectively decrease Aß1-42 production without inhibiting the production of other forms of Aß. Here we describe the novel discovery of synergistic inhibition of Aß by certain combinations of GSMs. Cell cultures were treated with pairwise combinations of GSMs to determine how Aß peptide production was affected. Analysis of isobolograms and calculation of the combination index showed that BMS-869780 and GSM-2 were highly synergistic. Additional combinations of GSMs revealed that inhibition of Aß occurred only when one GSM was of the "acid GSM" structural class and the other was of the "non-acid GSM" class. A total of 15 representative acid/non-acid GSM combinations were shown to inhibit Aß production, whereas 10 pairwise combinations containing two acid GSMs or containing two non-acid GSMs did not inhibit Aß. We also discovered that lasalocid, a natural product, is a potent GSM. Lasalocid is unique in that it did not synergize with other GSMs. Synergism did not translate in vivo perhaps because of biochemical differences between the cell culture model and brain. These findings reinforce the pharmacological differences between different structural classes of GSMs, and may help to exploit the potential of γ-secretase as a drug target.
Sujet(s)
Amyloid precursor protein secretases/antagonistes et inhibiteurs , Peptides bêta-amyloïdes/biosynthèse , Fragments peptidiques/biosynthèse , Inhibiteurs de protéases/pharmacologie , Acétates/pharmacologie , Animaux , Lignée cellulaire tumorale , Synergie des médicaments , Humains , Souris , Pipéridines/pharmacologieRÉSUMÉ
Alzheimer's disease is the most prevalent cause of dementia and is associated with accumulation of amyloid-ß peptide (Aß), particularly the 42-amino acid Aß1-42, in the brain. Aß1-42 levels can be decreased by γ-secretase modulators (GSM), which are small molecules that modulate γ-secretase, an enzyme essential for Aß production. BMS-869780 is a potent GSM that decreased Aß1-42 and Aß1-40 and increased Aß1-37 and Aß1-38, without inhibiting overall levels of Aß peptides or other APP processing intermediates. BMS-869780 also did not inhibit Notch processing by γ-secretase and lowered brain Aß1-42 without evidence of Notch-related side effects in rats. Human pharmacokinetic (PK) parameters were predicted through allometric scaling of PK in rat, dog, and monkey and were combined with the rat pharmacodynamic (PD) parameters to predict the relationship between BMS-869780 dose, exposure and Aß1-42 levels in human. Off-target and safety margins were then based on comparisons to the predicted exposure required for robust Aß1-42 lowering. Because of insufficient safety predictions and the relatively high predicted human daily dose of 700 mg, further evaluation of BMS-869780 as a potential clinical candidate was discontinued. Nevertheless, BMS-869780 demonstrates the potential of the GSM approach for robust lowering of brain Aß1-42 without Notch-related side effects.
RÉSUMÉ
A convergent synthesis route for the heterocyclic modification of a novel bicyclo[3.1.0]hexane NPY1 antagonist 2 was developed and the structure activity relationship of these modifications on NPY1 binding is reported. Two heterocyclic analogs 9 and 10 showed comparable Y1 binding potency to 2, but with improved aqueous solubility. Compound 9 demonstrated reduced spontaneous nocturnal food intake in a rat model when dosed ip. Compound 9 was also shown to be orally bioavailable and brain penetrable.
Sujet(s)
Composés bicycliques pontés/pharmacologie , Composés hétérocycliques/pharmacologie , Récepteur neuropeptide Y/antagonistes et inhibiteurs , Administration par voie orale , Animaux , Composés bicycliques pontés/administration et posologie , Composés bicycliques pontés/composition chimique , Relation dose-effet des médicaments , Composés hétérocycliques/administration et posologie , Composés hétérocycliques/composition chimique , Mâle , Structure moléculaire , Rats , Rat Sprague-Dawley , Relation structure-activitéRÉSUMÉ
This report describes the discovery and optimization of a BACE-1 inhibitor series containing an unusual acyl guanidine chemotype that was originally synthesized as part of a 6041-membered solid-phase library. The synthesis of multiple follow-up solid- and solution-phase libraries facilitated the optimization of the original micromolar hit into a single-digit nanomolar BACE-1 inhibitor in both radioligand binding and cell-based functional assay formats. The X-ray structure of representative inhibitors bound to BACE-1 revealed a number of key ligand:protein interactions, including a hydrogen bond between the side chain amide of flap residue Gln73 and the acyl guanidine carbonyl group, and a cation-π interaction between Arg235 and the isothiazole 4-methoxyphenyl substituent. Following subcutaneous administration in rats, an acyl guanidine inhibitor with single-digit nanomolar activity in cells afforded good plasma exposures and a dose-dependent reduction in plasma Aß levels, but poor brain exposure was observed (likely due to Pgp-mediated efflux), and significant reductions in brain Aß levels were not obtained.
Sujet(s)
Amyloid precursor protein secretases/antagonistes et inhibiteurs , Aspartic acid endopeptidases/antagonistes et inhibiteurs , Guanidines/synthèse chimique , Bibliothèques de petites molécules , Amyloid precursor protein secretases/composition chimique , Peptides bêta-amyloïdes/métabolisme , Précurseur de la protéine bêta-amyloïde/génétique , Animaux , Aspartic acid endopeptidases/composition chimique , Encéphale/métabolisme , Lignée cellulaire , Cristallographie aux rayons X , Guanidines/pharmacocinétique , Guanidines/pharmacologie , Humains , Isoxazoles/synthèse chimique , Isoxazoles/pharmacocinétique , Isoxazoles/pharmacologie , Modèles moléculaires , Structure moléculaire , Mutation , Fragments peptidiques/métabolisme , Liaison aux protéines , Dosage par compétition , Rats , Techniques de synthèse en phase solide , Solutions , Relation structure-activitéRÉSUMÉ
A novel class of bicyclo[3.1.0]hexanylpiperazine neuropeptide Y (NPY) Y1 antagonists has been designed and synthesized. Scatchard binding analysis showed these compounds to be noncompetitive with [(125)I]PYY binding to the Y1 receptor. The most potent member, 1-((1α,3α,5α,6ß)-6-(3-ethoxyphenyl)-3-methylbicyclo[3.1.0]hexan-6-yl)-4-phenylpiperazine (2) had an IC50 = 62 nM and displayed excellent oral bioavailability in rat (% F po = 80), as well as good brain penetration (B/P ratio = 0.61). In a spontaneous nocturnal feeding study with male Sprague-Dawley rats, 2 significantly reduced food intake during a 12 h period.
RÉSUMÉ
In this report we describe a novel radioligand, [(3)H](S)-2-((S)-3-Acetylamino-3-sec-butyl-2-oxo-pyrrolidin-1-yl)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-methoxy-benzylamino)-propyl]-4-phenyl-butyramide ([(3)H]BMS-599240), that exhibits robust specific binding in homogenates from cell cultures overexpressing beta-site amyloid precursor protein cleaving enzyme-1 (BACE1). Radioligand binding exhibited high affinity, K(d)=2 nM, commensurate with its inhibitory potency against BACE1. Inhibition of radioligand binding in the presence of a range of different BACE1 inhibitors exhibited the same rank order of potency as for inhibition of BACE1 enzymatic activity. BACE1-dependent binding of the radioligand was also demonstrated in mouse brain homogenates, where genetic ablation of BACE1 eliminated high affinity binding. Thus, the radioligand [(3)H]BMS-599240 is a novel tool potentially useful for evaluation of BACE1 enzyme in biological samples, and for evaluation of inhibitor binding to BACE1.
Sujet(s)
Amyloid precursor protein secretases/antagonistes et inhibiteurs , Aspartic acid endopeptidases/antagonistes et inhibiteurs , Pyrrolidones , Amyloid precursor protein secretases/biosynthèse , Amyloid precursor protein secretases/génétique , Animaux , Aspartic acid endopeptidases/biosynthèse , Aspartic acid endopeptidases/génétique , Encéphale/cytologie , Cellules cultivées , ADN complémentaire/biosynthèse , ADN complémentaire/génétique , Humains , Cinétique , Ligands , Souris , Protéines proto-oncogènes c-myc/métabolisme , Dosage par compétitionRÉSUMÉ
The amyloid-beta (Abeta) peptide, which likely plays a key role in Alzheimer disease, is derived from the amyloid-beta precursor protein (APP) through consecutive proteolytic cleavages by beta-site APP-cleaving enzyme and gamma-secretase. Unexpectedly gamma-secretase inhibitors can increase the secretion of Abeta peptides under some circumstances. This "Abeta rise" phenomenon, the same inhibitor causing an increase in Abeta at low concentrations but inhibition at higher concentrations, has been widely observed. Here we show that the Abeta rise depends on the beta-secretase-derived C-terminal fragment of APP (betaCTF) or C99 levels with low levels causing rises. In contrast, the N-terminally truncated form of Abeta, known as "p3," formed by alpha-secretase cleavage, did not exhibit a rise. In addition to the Abeta rise, low betaCTF or C99 expression decreased gamma-secretase inhibitor potency. This "potency shift" may be explained by the relatively high enzyme to substrate ratio under conditions of low substrate because increased concentrations of inhibitor would be necessary to affect substrate turnover. Consistent with this hypothesis, gamma-secretase inhibitor radioligand occupancy studies showed that a high level of occupancy was correlated with inhibition of Abeta under conditions of low substrate expression. The Abeta rise was also observed in rat brain after dosing with the gamma-secretase inhibitor BMS-299897. The Abeta rise and potency shift are therefore relevant factors in the development of gamma-secretase inhibitors and can be evaluated using appropriate choices of animal and cell culture models. Hypothetical mechanisms for the Abeta rise, including the "incomplete processing" and endocytic models, are discussed.
Sujet(s)
Amyloid precursor protein secretases/métabolisme , Peptides bêta-amyloïdes/métabolisme , Régulation de l'expression des gènes codant pour des enzymes , Animaux , Encéphale/métabolisme , Butyrates/pharmacologie , Lignée cellulaire , Antienzymes/pharmacologie , Femelle , Humains , Hydrocarbures halogénés/pharmacologie , Souris , Liaison aux protéines , Structure tertiaire des protéines , Rats , Spécificité du substratRÉSUMÉ
Treatment of obesity is still a large unmet medical need. Neuropeptide Y is the most potent orexigenic peptide in the animal kingdom. Its five cloned G-protein couple receptors are all implicated in the regulation of energy homeostasis evidenced by overexpression or deletion of neuropeptide Y or its receptors. Neuropeptide Y most likely exerts its orexigenic activity via the neuropeptide Y(1) and neuropeptide Y(5) receptors, although the involvement of the neuropeptide Y(2) and neuropeptide Y(4) receptors are also gaining importance. The lack of potent, selective, and brain penetrable pharmacologic agents at these receptors made our understanding of the modulation of food intake by neuropeptide Y-ergic agents elusive. BMS-193885 (1,4-dihydro-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino] carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester) is a potent and selective neuropeptide Y(1) receptor antagonist. BMS-193885 has 3.3 nM affinity at the neuropeptide Y(1) receptor, acting competitively at the neuropeptide Y binding site. BMS-193885 increased the K(d) of [(125)I]PeptideYY from 0.35 nM to 0.65 nM without changing the B(max) (0.16 pmol/mg of protein) in SK-N-MC cells that endogenously express the neuropeptide Y(1) receptor. It is also found to be a full antagonist with an apparent K(b) of 4.5 nM measured by reversal of forskolin (FK)-stimulated inhibition of cAMP production by neuropeptide Y. Pharmacological profiling showed that BMS-193885 has no appreciable affinity at the other neuropeptide Y receptors, and is also 200-fold less potent at the alpha(2) adrenergic receptor. Testing the compound in a panel of 70 G-protein coupled receptors and ion channels resulted in at least 200-fold or greater selectivity, with the exception of the sigma(1) receptor, where the selectivity was 100-fold. When administered intracerebroventricularly or directly into the paraventricular nucleus of the hypothalamus, it blocked neuropeptide Y-induced food intake in rats. Intraperitoneal administration of BMS-193885 (10 mg/kg) also reduced one-hour neuropeptide Y-induced food intake in satiated rats, as well as spontaneous overnight food consumption. Chronic administration of BMS-193885 (10 mg/kg) i.p. for 44 days significantly reduced food intake and the rate of body weight gain compared to vehicle treated control without developing tolerance or affecting water intake. These results provide supporting evidence that BMS-193885 reduces food intake and body weight via inhibition of the central neuropeptide Y(1) receptor. BMS-193885 has no significant effect of locomotor activity up to 20 mg/kg dose after 1 h of treatment. It also showed no activity in the elevated plus maze when tested after i.p. and i.c.v. administration, indicating that reduction of food intake is unrelated to anxious behavior. BMS-193885 has good systemic bioavailability and brain penetration, but lacks oral bioavailability. The compound had no serious cardiovascular adverse effect in rats and dogs up to 30 and 10 mg/kg dose, respectively, when dosed intravenously. These data demonstrate that BMS-193885 is a potent, selective, brain penetrant Y(1) receptor antagonist that reduces food intake and body weight in animal models of obesity both after acute and chronic administration. Taken together the data suggest that a potent and selective neuropeptide Y(1) receptor antagonist might be an efficacious treatment for obesity in humans.
Sujet(s)
Anorexigènes/pharmacologie , Dihydropyridines/pharmacologie , Phénylurées/pharmacologie , Récepteur neuropeptide Y/antagonistes et inhibiteurs , Animaux , Cellules CHO , Lignée cellulaire tumorale , Cricetinae , Cricetulus , Dihydropyridines/pharmacocinétique , Consommation alimentaire/effets des médicaments et des substances chimiques , Humains , Injections ventriculaires , Mâle , Neuropeptide Y/physiologie , Phénylurées/pharmacocinétique , Rats , Rat Sprague-DawleyRÉSUMÉ
Alzheimer's disease (AD) is a progressive neurodegenerative disease. Amyloid beta (Abeta) peptides are hypothesized to cause the initiation and progression of AD based on pathologic data from AD patients, genetic analysis of mutations that cause early onset forms of AD, and preclinical studies. Based on this hypothesis, beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) inhibitors are an attractive therapeutic approach for AD because cleavage of the APP by BACE1 is required to form Abeta. In this study, three potent BACE1 inhibitors are characterized. All three inhibitors decrease Abeta formation in cultured cells with IC(50) values less than 10 nM. Analysis of APP C-terminal fragments by immunoblotting and Abeta peptides by mass spectrometry showed that these inhibitors decreased Abeta by inhibiting BACE1. An assay for Abeta1-40 in mice was developed and used to show that these BACE1 inhibitors decreased plasma Abeta1-40, but not brain Abeta1-40, in wild-type mice. Because these BACE1 inhibitors were substrates for P-glycoprotein (P-gp), a member of the ATP-binding cassette superfamily of efflux transporters, these inhibitors were administered to P-gp knockout (KO) mice. These studies showed that all three BACE1 inhibitors decreased brain Abeta1-40 in P-gp KO mice, demonstrating that P-gp is a major limitation for development of BACE1 inhibitors to test the amyloid hypothesis. A comparison of plasma Abeta1-40 and brain Abeta1-40 dose responses for these three compounds revealed differences in relative ED(50) values, indicating that factors other than P-gp can also contribute to poor brain activity by BACE1 inhibitors.
Sujet(s)
Glycoprotéine P/métabolisme , Amyloid precursor protein secretases/antagonistes et inhibiteurs , Peptides bêta-amyloïdes/métabolisme , Aspartic acid endopeptidases/antagonistes et inhibiteurs , Encéphale , Antienzymes/pharmacologie , Fragments peptidiques/métabolisme , Glycoprotéine P/génétique , Amyloid precursor protein secretases/physiologie , Peptides bêta-amyloïdes/sang , Précurseur de la protéine bêta-amyloïde/génétique , Précurseur de la protéine bêta-amyloïde/métabolisme , Animaux , Aspartic acid endopeptidases/physiologie , Technique de Western , Encéphale/effets des médicaments et des substances chimiques , Encéphale/enzymologie , Encéphale/métabolisme , Lignée cellulaire , Perméabilité des membranes cellulaires , Antienzymes/synthèse chimique , Antienzymes/composition chimique , Antienzymes/pharmacocinétique , Test ELISA , Humains , Souris , Souris knockout , Structure moléculaire , Fragments peptidiques/sang , Liaison aux protéines , Spécificité du substratRÉSUMÉ
The enzyme gamma-secretase has long been considered a potential pharmaceutical target for Alzheimer disease. Presenilin (the catalytic subunit of gamma-secretase) and signal peptide peptidase (SPP) are related transmembrane aspartyl proteases that cleave transmembrane substrates. SPP and gamma-secretase are pharmacologically similar in that they are targeted by many of the same small molecules, including transition state analogs, non-transition state inhibitors, and amyloid beta-peptide modulators. One difference between presenilin and SPP is that the proteolytic activity of presenilin functions only within a multisubunit complex, whereas SPP requires no additional protein cofactors for activity. In this study, gamma-secretase inhibitor radioligands were used to evaluate SPP and gamma-secretase inhibitor binding pharmacology. We found that the SPP enzyme exhibited distinct binding sites for transition state analogs, non-transition state inhibitors, and the nonsteroidal anti-inflammatory drug sulindac sulfide, analogous to those reported previously for gamma-secretase. In the course of this study, cultured cells were found to contain an abundance of SPP binding activity, most likely contributed by several of the SPP family proteins. The number of SPP binding sites was in excess of gamma-secretase binding sites, making it essential to use selective radioligands for evaluation of gamma-secretase binding under these conditions. This study provides further support for the idea that SPP is a useful model of inhibitory mechanisms and structure in the SPP/presenilin protein family.
Sujet(s)
Amyloid precursor protein secretases/antagonistes et inhibiteurs , Anti-inflammatoires non stéroïdiens/pharmacologie , Aspartic acid endopeptidases/antagonistes et inhibiteurs , Présénilines/antagonistes et inhibiteurs , Inhibiteurs de protéases/pharmacologie , Sulindac/analogues et dérivés , Maladie d'Alzheimer/enzymologie , Amyloid precursor protein secretases/métabolisme , Peptides bêta-amyloïdes/antagonistes et inhibiteurs , Peptides bêta-amyloïdes/métabolisme , Aspartic acid endopeptidases/métabolisme , Sites de fixation , Domaine catalytique , Lignée cellulaire , Humains , Ligands , Modèles moléculaires , Présénilines/métabolisme , Sulindac/pharmacologieRÉSUMÉ
Reduction of brain beta-amyloid peptide (Abeta) synthesis by gamma-secretase inhibitors is a promising approach for the treatment of Alzheimer's disease. However, measurement of central pharmacodynamic effects in the Alzheimer's disease patient will be a challenge. Determination of drug occupancy may facilitate the analysis of efficacy of gamma-secretase inhibitors in a clinical setting. In this study, the relationship of gamma-secretase site occupancy and brain Abeta40 reduction by gamma-secretase inhibitors was examined in Tg2576 mice. [3H](2R,3S)-2-Isobutyl-N1-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-propylsuccinamide (IN973) was used as a gamma-secretase radioligand, since it has been shown to bind to gamma-secretase in rat, rhesus, and human brains with high affinity and specificity. We extended these findings by showing that [3H]IN973 bound to gamma-secretase in Tg2576 brains with an affinity, specificity, and regional localization very similar to the other species. To quantify gamma-secretase occupancy by gamma-secretase inhibitors, an ex vivo binding assay was developed using [3H]IN973 and frozen brain sections from drug-treated mice. Gamma-secretase occupancy and brain Abeta40 reduction were found to be highly correlated in animals dosed with either 2-[(1R)-1-[[4-chlorophenyl)-sulfonyl](2,5-difluorophenyl)amino] ethyl]-5-fluoro-benzenepropanoic acid (BMS-299897) or (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796) over a wide range of doses and times postdose, with the exception of the earliest times postdose. This lag in Abeta40 response to gamma-secretase inhibition is probably related to the delayed clearance of previously produced Abeta40. The excellent correlation between brain Abeta40 and gamma-secretase occupancy suggests that a positron emission tomography ligand for gamma-secretase could be a valuable biomarker to determine whether gamma-secretase inhibitors bind to their target in humans.
Sujet(s)
Amyloid precursor protein secretases/antagonistes et inhibiteurs , Précurseur de la protéine bêta-amyloïde/biosynthèse , Encéphale/enzymologie , Antienzymes/pharmacologie , Précurseur de la protéine bêta-amyloïde/génétique , Animaux , Sites de fixation , Encéphale/effets des médicaments et des substances chimiques , Encéphale/métabolisme , Relation dose-effet des médicaments , Antienzymes/composition chimique , Ligands , Souris , Souris transgéniques , Structure moléculaire , Dosage par compétition , Facteurs tempsRÉSUMÉ
A series of novel 5,5-diphenylimidazolones was synthesized and evaluated for activity against the human neuropeptide Y5 receptor. The 3-pyridyl analog 46 demonstrated an IC(50) of 8.3 nM with a favorable pharmacokinetic profile in rats, but was ineffective in reducing food intake.
Sujet(s)
Agents antiobésité/pharmacologie , Consommation alimentaire/effets des médicaments et des substances chimiques , Imidazoles/pharmacologie , Récepteur neuropeptide Y/antagonistes et inhibiteurs , Animaux , Agents antiobésité/synthèse chimique , Humains , Imidazoles/synthèse chimique , Concentration inhibitrice 50 , Dosage par compétition , Rats , Rat Sprague-Dawley , Récepteur neuropeptide Y/métabolisme , Relation structure-activité , Facteurs tempsRÉSUMÉ
(R)-2-(4-Phenylbutyl)dihydrobenzofuran derivatives (e.g., 3 and 4) were synthesized as novel melatoninergic ligands with significantly lower vasoconstrictive activity in vitro in the rat tail artery. Binding affinity assays were performed on cloned human MT1 and MT2 receptors stably expressed in NIH3T3 cells.
Sujet(s)
Benzofuranes/composition chimique , Benzofuranes/pharmacologie , Mélatonine/agonistes , Vasoconstricteurs/composition chimique , Vasoconstricteurs/pharmacologie , Animaux , Benzofuranes/synthèse chimique , Clonage moléculaire , Humains , Ligands , Mélatonine/pharmacologie , Souris , Structure moléculaire , Cellules NIH 3T3 , Liaison aux protéines/effets des médicaments et des substances chimiques , Rats , Récepteur de la mélatonine de type MT1/effets des médicaments et des substances chimiques , Récepteur de la mélatonine de type MT1/métabolisme , Récepteur de la mélatonine de type MT2/effets des médicaments et des substances chimiques , Récepteur de la mélatonine de type MT2/métabolisme , Protéines recombinantes/effets des médicaments et des substances chimiques , Protéines recombinantes/métabolisme , Relation structure-activité , Vasoconstriction/effets des médicaments et des substances chimiques , Vasoconstricteurs/synthèse chimiqueRÉSUMÉ
A series of tetrahydroisoquinolines has yielded potent MT(2) receptor antagonists, which are selective versus the MT(1) receptor.
Sujet(s)
Récepteur de la mélatonine de type MT2/antagonistes et inhibiteurs , Récepteur de la mélatonine de type MT2/métabolisme , Tétrahydroisoquinoléines/composition chimique , Tétrahydroisoquinoléines/métabolisme , Humains , Liaison aux protéines/physiologieRÉSUMÉ
N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide 3a was synthesized as an orally bioavailable agonist at MT1 and MT2 melatonin receptors with significantly low vasoconstrictive activity.
Sujet(s)
Acétamides/pharmacocinétique , Benzofuranes/pharmacocinétique , Récepteur de la mélatonine de type MT1/agonistes , Récepteur de la mélatonine de type MT2/agonistes , Acétamides/synthèse chimique , Acétamides/toxicité , Administration par voie orale , Animaux , Benzofuranes/synthèse chimique , Benzofuranes/toxicité , Biodisponibilité , AMP cyclique/antagonistes et inhibiteurs , AMP cyclique/biosynthèse , Relation dose-effet des médicaments , Humains , Techniques in vitro , Souris , Contraction musculaire/effets des médicaments et des substances chimiques , Muscles lisses vasculaires/effets des médicaments et des substances chimiques , Muscles lisses vasculaires/physiologie , Cellules NIH 3T3 , Dosage par compétition , Rats , Relation structure-activitéRÉSUMÉ
Conformationally constrained aryl cyclohexanes and cyclohexenes based on aryl cyclohexanols 1 were prepared. Locking the aryl ring in plane with the cyclohexane moiety provided potent SSRIs 3. Conversely, fixing the aryl ring perpendicular to the cyclohexane ring via a spiro lactone provided balanced 5-HT1A antagonists with mid-nanomolar range SSRI potency (compounds 2).
Sujet(s)
Récepteur de la sérotonine de type 5-HT1A/métabolisme , Inbiteurs sélectifs de la recapture de la sérotonine/composition chimique , Inbiteurs sélectifs de la recapture de la sérotonine/métabolisme , Sérotonine/métabolisme , Ligands , Conformation moléculaireRÉSUMÉ
A series of benzoxazole derivatives was synthesized and evaluated as melatoninergic ligands. The binding affinity of these compounds for human MT(1) and MT(2) receptors was determined using 2-[(125)I]-iodomelatonin as the radioligand. From this series of benzoxazole derivatives, compounds 14 and 17 were identified as melatonin receptor agonists.
Sujet(s)
Benzoxazoles/synthèse chimique , Récepteurs à la mélatonine/agonistes , Benzoxazoles/pharmacologie , Sites de fixation , Lignée cellulaire , Conception de médicament , Humains , Ligands , Mélatonine/analogues et dérivés , Mélatonine/métabolisme , Dosage par compétition , Récepteurs de surface cellulaire/effets des médicaments et des substances chimiques , Récepteurs à la mélatonine/métabolisme , Relation structure-activitéRÉSUMÉ
A series of 4-substituted anilides with human melatonergic affinity is reported. Butyramides 26, 39, 42, 52, 57, and 58 all demonstrated subnanomolar MT(2) binding affinity and MT(2) selectivity of at least 70-fold over the MT(1) receptor. Compound 26 demonstrated full agonism at the MT(2) receptor.
Sujet(s)
Anilides/composition chimique , Récepteur de la mélatonine de type MT2/agonistes , Anilides/synthèse chimique , Fixation compétitive , Humains , Mélatonine/métabolisme , Structure moléculaire , Récepteur de la mélatonine de type MT2/composition chimique , Relation structure-activitéRÉSUMÉ
A novel series of benzoxazole derivatives was synthesized and evaluated as melatoninergic ligands. The binding affinity of these compounds for human MT(1) and MT(2) receptors was determined using 2-[(125)I]-iodomelatonin as the radioligand. The results of the SAR studies in this series led to the identification of compound 28, which exhibited better MT(1) and MT(2) receptor affinities than melatonin itself. This work also established the benzoxazole nucleus as a melatoninergic pharmacophore, which served as an isosteric replacement to the previously established alkoxyaryl core.
Sujet(s)
Benzoxazoles/synthèse chimique , Benzoxazoles/métabolisme , Mélatonine/composition chimique , Mélatonine/physiologie , Récepteurs à la mélatonine/physiologie , Conception de médicament , Humains , Ligands , Mélatonine/métabolisme , Liaison aux protéinesRÉSUMÉ
beta-Alanine derivative 2 (IC(50)=16 nM) and related compounds were found to be potent MC4R agonists.